Related Experiment Videos
CD44 expression is associated with increased survival in node-negative invasive breast carcinoma
Leslie K Diaz1, Xiao Zhou, Edward T Wright
1Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Summary
High CD44 standard isoform (CD44s) expression may indicate a favorable prognosis in early-stage breast cancer patients. This finding suggests CD44s positivity is a potential biomarker for improved disease-related survival in node-negative invasive breast carcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Research
Background:
- CD44 is a cell surface receptor with splice variants implicated in tumor progression.
- Understanding CD44 isoform roles is crucial for predicting breast cancer outcomes.
Purpose of the Study:
- To investigate the prognostic value of CD44 isoforms in early-stage, lymph node-negative invasive breast carcinoma.
- To correlate CD44 standard (CD44s) and variant 6 (CD44v6) expression with patient survival.
Main Methods:
- Immunohistochemical staining of CD44s and CD44v6 on invasive breast carcinoma tissue from node-negative patients.
- Correlation of staining levels with clinical outcomes over a 15-year follow-up period.
- Patients did not receive adjuvant tamoxifen or chemotherapy.
Main Results:
- A trend towards increased disease-free survival was observed with high CD44s positivity (P=0.05).
- Significant association found between CD44s positivity and improved disease-related survival (P=0.04).
- CD44v6 expression did not correlate with clinical outcome.
Conclusions:
- CD44s expression, detected via immunohistochemistry, may serve as a favorable prognostic factor.
- CD44s positivity could identify node-negative invasive breast carcinoma patients with better outcomes.
- Further research into CD44s as a prognostic biomarker is warranted.